psoriasis therapy (OSI Pharmaceuticals)

N/A

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug Namepsoriasis therapy (OSI Pharmaceuticals)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEpidermal growth factor receptor erbB1 inhibitorsVascular endothelial growth factor receptor inhibitors
TargetsEpidermal growth factor receptor erbB1Vascular endothelial growth factor receptor
Therapy Area/IndicationsPsoriasis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPfizer IncOsi Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsPsoriasis

Other Information

ATC CodeN/A
Related LinksN/A